Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex
What this study shows
Mice lacking Tsc1 mainly in glial cells (Tsc1 GFAP conditional knockout) develop glial overgrowth, progressive epilepsy and early death. Rapamycin started at postnatal day 14, before symptoms, prevented epilepsy and premature death; started at 6 weeks, after seizures had begun, it suppressed seizures and prolonged survival. In the brain, rapamycin reversed the abnormal mTOR pathway activation (measured as phospho-S6), the astrogliosis and the neuronal disorganisation, and increased brain size, compared with vehicle-treated knockouts. The study provided evidence in mice that mTOR inhibition can act on epilepsy itself in TSC, not only on tumours, and it is part of the rationale for the later EXIST-3 seizure trial in patients. Boundary: mouse model with Tsc1 deleted mainly in glia, not the human germline mutation; seizure and survival outcomes in mice only; abstract does not state dose or schedule.
At a glance
| Evidence type | A Animal model Marked A because it is an animal intervention or observation study measuring an organismal outcome (model: Mice: Tsc1(GFAP) conditional knockout (Tsc1 deleted mainly in glia) and littermate controls; rapamycin or vehicle from P14 (early) or 6 weeks (late); video-EEG, survival, histology, Western blot for phospho-S6); the code names the system studied -- animal work can be rigorous and still not be human data. |
| Study type | 4 - Animal Study |
| Model system | Mice: Tsc1(GFAP) conditional knockout (Tsc1 deleted mainly in glia) and littermate controls; rapamycin or vehicle from P14 (early) or 6 weeks (late); video-EEG, survival, histology, Western blot for phospho-S6 |
| Journal | Annals of Neurology |
| Year | 2008 |
| Peer reviewed | Yes |
| Record last updated | 2026-10-01 |
| Source | DOI 10.1002/ana.21331 · PMID 18389497 · Free full text (PMC3937593) |
Extracted findings
These fields were extracted from the paper with AI assistance and have not been checked against the source. Read them as a pointer into the paper, not as curated claims; where they disagree with the curated summary above, the curated summary stands.
| Intervention | Rapamycin vs vehicle, early (from P14) or late (from 6 weeks) |
| Target | mTORC1 |
| Model | Mouse |
| Effect | Prevented (early) or suppressed (late) epilepsy and prolonged survival; reduced phospho-S6, astrogliosis, neuronal disorganisation |
In the Atlas
Related topics
Links in the pathway map
- Supports TSC1/TSC2 inhibits mTORC1
More studies on this topic
- Excitatory/inhibitory synaptic imbalance leads to hippocampal hyperexcitability in mouse models of tuberous sclerosis (2013)
- Reversal of learning deficits in a Tsc2+/- mouse model of tuberous sclerosis (2008)
- A mouse model of TSC1 reveals sex-dependent lethality from liver hemangiomas, and up-regulation of p70S6 kinase activity in Tsc1 null cells (2002)
- mTORC1 drives cell-autonomous astrocyte reactivity in tuberous sclerosis (2026)
Thank you. Your answer was counted anonymously.